

Original Article

Synthesis of Novel Thiazolidinone and Its Application as Apha-Amylase Inhibitor

Ramdas N Ingole¹, Rameshwar M. More², Shivraj B. Patil³, Kishor A. Dawane⁴,
Gajanan G. Kadam^{5*}

¹Shri Vitthal Rukmini Arts, Commerce and Science College, Sawana

^{2,3,4,5}Shri Datta Arts, Commerce and Science College, Hadgaon, Dist.-Nanded

Manuscript ID:
IBMIIRJ -2025-020702

Submitted: 08 June 2025

Revised: 24 June 2025

Accepted: 11 July 2025

Published: 31 July 2025

ISSN: 3065-7857

Volume-2

Issue-7

Pp. 5-8

July 2025

Correspondence Address:

Ramdas N Ingole,
Shri Vitthal Rukmini Arts, Commerce
and Science College, Sawana
Email:

Kadam.gajanan431@gmail.com



Quick Response Code:



Web: <https://ibrj.us>



DOI: 10.5281/zenodo.16602593

DOI Link:

<https://doi.org/10.5281/zenodo.16602593>



Creative Commons

Abstract:

In organic and medicinal chemistry, thiazolidinone and its derivatives are crucial because they have nearly all biological activities, including antimicrobial, anti-tubercular, anti-diarrheal, and anticonvulsant properties. We tried to synthesize thiazolidinone from a schiff base that garnered a lot more attention in order to achieve notable biological activities. Design and mild-condition synthesis of a new substituted thiazolidinone from 2-amino-thiazole and pyrazole-2-aldehyde using DCC. Derivatives substituted with thiazolidinone were discovered to be useful in inhibiting α -amylase.

Keywords: Schiff base, DCC, α -amylase, and thiazolidinone

Introduction:

One common therapeutic target used to treat and maintain postprandial blood glucose elevations is α -amylase. Diabetes mellitus is a metabolic disorder that develops when the body cannot properly use insulin, a crucial hormone that controls blood glucose levels, or when the pancreas is unable to produce enough of it. Type 1 diabetes and insulin-dependent diabetes, also known as juvenile diabetes, are the two main types of diabetes mellitus. On the other hand, type-2 diabetes typically affects adults and is frequently brought on by the body's inability to secrete enough insulin or its resistance to it. Type-2 diabetes now affects over 95% of the population. An astounding 422 million people worldwide suffer from diabetes, with low- to medium-income countries accounting for the majority of cases. Recently, α -amylase and α -glucosidase enzyme suppression has been used to treat diabetes. The calcium metalloenzyme α -amylase is essential for digestion because it encourages the breakdown of polysaccharide molecules into simpler forms like glucose and maltose. Among other things, the enzyme raises blood glucose levels and causes postprandial hyperglycemia. One common therapeutic target used to treat and maintain postprandial blood glucose elevations is α -amylase. By catalyzing the α -(1,4)-D-glycosidic bonds found in starch, it produces antioxidants. Both reactive oxygen species (ROS) and nitrogen species, which were derived from oxygen and nitrogen, respectively, make up the reactive molecule. The cellular membrane, mitochondria, nucleus, lysosome, peroxisome, endoplasmic reticulum, and cytoplasm are among the subcellular organelles that produce reactive particles. By donating electrons to free radicals or reactive oxygen species, antioxidants are molecular compounds that have strong scavenging properties that transform them into benign substances.

Experimental:

General procedure for the synthesis of substituted thiazolidin-4-one (3)

A mixture of substituted phenyl-2- aminothiazole 1 (0.61 mmol), pyrazole-4-carboxaldehyde 2 (0.56 mmol), and pyridine (2.13 mmol) in toluene (10 mL) was heated to 130°C for 20 hours in a 25 mL round-bottom flask. Thin layer chromatography was used to monitor the reaction's progress. Following the completion of the reaction, the mixture was vacuum-evaporated before 1 mL of diethyl ether was added. Thioglycolic acid (68 mg, 0.737 mmol) was added to the separated yellow solid in 10 mL of THF, and it was stirred for 30 minutes at room temperature.

Creative Commons (CC BY-NC-SA 4.0)

This is an open access journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-nc-sa/4.0/) Public License, which allows others to remix, tweak, and build upon the work noncommercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article:


Ingole, R. N., More, R. M., Patil, S. B., Dawane, K. A., & Kadam, G. G. (2025). Synthesis of Novel Thiazolidinone and Its Application as Apha-Amylase Inhibitor. *Insight Bulletin: A Multidisciplinary Interlink International Research Journal*, 2(7), 5–8. <https://doi.org/10.5281/zenodo.16602593>

DCC (152 mg, 0.737 mmol) was added to the reaction mixture in portions after it had cooled. Thin layer chromatography was used to track the reaction's development. Once the reaction was finished, crushed ice was added. The solid product was taken out.

Results and discussion:


Our experiment began with the condensation of pyrazole-3-carbaldehyde and 2-amino-thiazole. We used substrates 1 and 2 as models to obtain substituted thiazolidin-4-one. Zinc chloride is typically used to treat schiff base and thioglycolic acid in order to produce substituted thiazolidin-4-one. We recently used pyridine as a base in toluene at 130 °C for 12 hours to create the schiff base hybrid from 2-amino-thiazole and pyrazole-3-carbaldehyde. A good yield of the corresponding Schiff base 1a was obtained.

Scheme:




Entry	Reagent	Time (h)	Solvents	Yield ^a (%)
a	Anhydrous ZnCl ₂	12	Toulene, THF, DMF, 1,4-Dioxane	NR
b	Cu(OAc) ₂	12	Toulene, THF, DMF, 1,4-Dioxane	NR
c	MgCl ₂	12	Toulene, THF, DMF, 1,4-Dioxane	NR
d	I ₂	12	Toulene, THF, DMF, 1,4-Dioxane	NR
e	DCC	6	THF ^b	87
f	HATU	6	THF	82
g	EDCL	12	THF	34
h	CDI	12	THF	21
i	HOBt	6	THF	NR
j	TPP	6	THF	NR

^aIsolated yield; ^bOther solvents were also studied



Synthesis of pyrazole carbaldehyde and Schiff base derivatives:

The prepared derivatives, designated as a-e, underwent structural validation through the use of elemental analysis, FTIR, and NMR, among other analytical techniques. An examination of the product's infrared spectra revealed that a band in the 1718–1725 cm⁻¹ range had disappeared, and a new band had appeared around 1609–1625 cm⁻¹. The azomethine functional moiety is manifested in this up-and-coming band ensemble. ¹H-NMR and ¹³C-NMR spectra were used to further validate the structures found in the product. The azomethine proton caused a singlet to appear at 9.40 ppm in the ¹H-NMR spectra, while the aldehyde proton peak at 10.03 ppm vanished. The carbonyl carbon peak at about 186.8 ppm was absent from the ¹³C-NMR spectra, and the azomethine carbon atom caused the emergence of a new signal at about 156.1 ppm. In addition, other signals originating from the three carbons of the pyrazole nucleus were detected in the range of 114.24–116.01 ppm, 130.07–130.90 ppm, and 150.20–152.89 ppm.



Reaction condition: **1** (0.56 mmol), **2** (0.56 mmol), Pyridine (1.99 mmol) in Toluene (10 mL) at 130 °C for 18 h; Isolated yield

Method for α -amylase inhibition activity:

Patil and his team's method was used to study amylase inhibition in vitro [15]. In short, 500 μ L of 0.1 M phosphate buffer pH 6.9 containing 0.5% α -amylase enzyme fungal diastase (Research Lab) was allowed to react with 500 μ L of the test compound 3a-n (1 mg/ml). 500 μ L of 1% starch soluble, extra pure (Loba chemie) in 0.1 M phosphate buffer pH 6.8 (Research Lab) was added following a 10-minute incubation period at 25 °C. once more incubated for 10 minutes at 25 °C. The controls underwent the same procedure, substituting buffer for 500 μ L of the enzyme. Following incubation, 1000 μ L of DNS (Loba Chemie) was added to the test and control samples. The standard medication is acarbose, which is an inhibitor of the α -amylase enzyme. After ten minutes in a boiling water bath, they were cooled. A spectrophotometer was used to measure the absorbance at 540 nm, and the formula $\text{Inhibition (\%)} = \frac{[\text{Abs } 540 (\text{control}) - \text{Abs } 540 (\text{extract}) \times 100]}{\text{Abs } 540 (\text{control})}$ was used to determine the percentage inhibition of the α -amylase enzyme.

Conclusion:

Using DCC as a ring closure reagent, we have created a mild and effective technique for the synthesis of thiazolidinone derivatives from the various 2-aminothiazole and pyrazole-aldehyde via schiff base formation. Regarding its MIC and IC₅₀ values for α -amylase inhibition, glucose uptake, and antioxidant activity, the synthesized compound demonstrated encouraging outcomes. To find the ideal concentration of the synthesized compound for each of these uses and to detect any possible adverse effects, more investigation is required. Furthermore, new and improved compounds with improved properties could be developed using the synthesized compound as a starting point. All things considered, the findings of this study make a significant contribution to the field of natural product chemistry and demonstrate the potential of compounds derived from plants as sources of innovative medicines and food additives..

Acknowledgment

I am sincere gratitude to the Principal and the Department of Chemistry of Shri Vitthal Rukmini Arts, Commerce and Science College, Sawana, and Shri Datta Arts, Commerce and Science College, Hadgaon, for providing the necessary laboratory facilities and support for this research work. We are also thankful to the faculty members and technical staff for their valuable assistance during the experimental phase of the study. Special thanks to the InSight Bulletin: A Multidisciplinary Interlink International Research Journal for providing a platform to publish our findings.

Financial support and sponsorship

Nil.

Conflicts of interest

The authors declare that there are no conflicts of interest regarding the publication of this paper

References:

1. J. Khawandana, Double or hybrid diabetes: A systematic review on disease prevalence, characteristics and risk factors, *Nutr. Diabetes* 33 (2019) 1.
2. A. Artasensi, A. Pedretti, G. Vistoli, L. Fumagalli, Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs, *Molecules* 25 (2020) 1987.
3. N. Kaur, V. Kumar, S.K. Nayak, P. Wadhwa, P. Kaur, S.K. Sahu, Alpha-amylase as molecular target for treatment of diabetes mellitus: A comprehensive review, *Chem. Bio. Drug Design* 98 (2021) 539–560.
4. A. Samrot, A. Vijay, A-Amylase activity of wild and mutant strains of *Bacillus* sp, *Internet J. Microbiol.* 6 (2008) 1–6.
5. Z.-M. Yang, J. Lin, L.-H. Chen, M. Zhang, W.-W. Chen, X.-R. Yang, The roles of AMY1 copies and protein expression in human salivary α -amylase activity, *Physiol. Behav.* 138 (2015) 173.

6. F.A. Van De Laar, P.L. Lucassen, R.P. Akkermans, E.H. Van De Lisdonk, G.E. Rutten, C. Van Weel, α -Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis, *Diabetes Care* 28 (2005) 154–163.
7. W. Liang, M. Chen, D. Zheng, J. He, M. Song, L. Mo, J. Feng, J. Lan, A novel damage mechanism: Contribution of the interaction between necroptosis and ROS
8. R. Rafique, K. M. Khan, S. Chigurupati, A. Wadood, A. U. Rehman, U. Salar, V. Venugopal, S. Shamim, M. Taha, S. Perveen, Synthesis, in vitro α -amylase inhibitory, and radicals (DPPH and ABTS) scavenging potentials of new N- sulfonohydrazide substituted indazoles. *Bioorg. Chem.* 94 (2020) 94, No. 103410.
9. J. Balzarini, B. Orzeszko-Krzesin'ska, J.K. Maurin, A. Orzeszko, Synthesis and anti- HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones, *Eur. J. Med. Chem.* 44 (2009) 303–311.
10. A.A. Chavan, N.R. Pai, Synthesis and antimicrobial screening of 5-arylidene-2-imino-4-thiazolidinones, *Arkivoc* 16 (2007) 148–155.
11. N. Trotsko, Antitubercular properties of thiazolidin-4-ones - A review, *Eur J Med Chem* 215 (2015) 113266.
12. K. Omar, A. Geronikaki, P. Zoumpoulakis, C. Camoutsis, M. Soković, A. Cirić,
13. J. Glamoclija, *Bioorg Med Chem* 18 (2010) 426–432.
14. N.D. Sonawane, C. Muanprasat, R. Nagatani Jr., Y. Song, A.S. Verkman, In vivo pharmacology and antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents, *J Pharm Sci.* 94 (2005) 134–143.
15. A.A. Muchandi, A.S. Jadhav, S.B. Patil, S.A. Patil, N.B. Jadhav, Antioxidant and In Vitro Antidiabetic Activity of Methanol Extract of Piper cubeba L, *Int. Res. J. Phar. Med. Sci.* 1 (2018) 1